Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN vs MINITRAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute myocardial infarction (IV formulation),Heart failure associated with acute myocardial infarction (IV),Anal fissure (topical, off-label),Esophageal spasm (off-label)
Acute angina pectoris,Prophylaxis of angina pectoris (prior to activities that may provoke an attack),Chronic angina (off-label: long-term prophylaxis),Heart failure associated with acute myocardial infarction (off-label)
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution.
Metabolized primarily by hepatic glutathione-organic nitrate reductase and cytochrome P450 enzymes (CYP3A4) to inorganic nitrite and denitrated metabolites; also undergoes extrahepatic metabolism in erythrocytes and vascular tissue.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal.
Approximately 60% bound to albumin.
Approximately 60% bound to plasma proteins (albumin).
Approximately 3.3 L/kg, indicating extensive distribution into tissues.
Vd is about 3 L/kg, indicating extensive tissue distribution.
Sublingual: 40–60% due to first-pass metabolism; buccal: 40–60%; transdermal: 10–20% (limited by skin permeability).
Transdermal: approximately 70-80% of the dose reaches systemic circulation.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (Cr Cl <30 m L/min) may have increased risk of adverse effects; monitor closely.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Consider 25% dose reduction; Child-Pugh Class C: Avoid use or use with extreme caution, consider 50% dose reduction.
No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution.
Safety and efficacy not established; limited data: IV infusion 0.25-1 mcg/kg/min titrated to effect; sublingual 5-10 mcg/kg per dose (max 0.6 mg) every 5-10 minutes as needed for angina.
Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance.
Start at lowest dose; sublingual 0.3 mg, transdermal 0.2 mg/hour; increased sensitivity to hypotension and syncope; monitor for orthostatic hypotension; may require reduced dosing frequency.
Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly.
Do not use nitroglycerin with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Concomitant use with soluble guanylyl cyclase stimulators (e.g., riociguat) is contraindicated.
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
Hypotension,Tachycardia,Paradoxical bradycardia,Increased intracranial pressure (use with caution in cerebral hemorrhage or head trauma),Hypertrophic cardiomyopathy (may exacerbate outflow obstruction),Tolerance with prolonged use (intermittent dosing with nitrate-free interval recommended),Abrupt withdrawal may precipitate angina
Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component,Concomitant use with phosphodiesterase-5 inhibitors (within 24 hours for sildenafil, vardenafil; 48 hours for tadalafil),Concomitant use with soluble guanylyl cyclase stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis,Pericardial tamponade,Restrictive cardiomyopathy,Acute myocardial infarction with low left ventricular filling pressure,Circulatory failure (shock)
Concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); acute circulatory failure; hypersensitivity to nitrates.
Avoid alcohol consumption while taking nitroglycerin due to risk of severe hypotension and syncope. No other significant food interactions.
Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions.
Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution in third trimester due to potential maternal hypotension reducing uteroplacental perfusion.
Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion.
Excreted into breast milk in very low amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for hypotension.
Likely excreted in breast milk. M/P ratio not established. Use with caution; monitor infant for hypotension.
No routine dose adjustment required; however, increased plasma volume may necessitate higher doses for therapeutic effect. Monitor clinical response.
No specific dose adjustments recommended, but use lowest effective dose due to potential for hypotension and decreased placental perfusion.
Use with caution in patients with hypertrophic obstructive cardiomyopathy due to risk of syncope. Nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension. Sublingual tablets should be taken at first sign of angina; if pain persists after 5 minutes, call 911. Tolerance develops with continuous exposure, so use nitrate-free intervals (10-12 hours daily) for transdermal patches. Administer intravenous nitroglycerin with non-PVC tubing to avoid drug absorption. Monitor for hypotension, reflex tachycardia, and headache. Do not use in patients with severe anemia, increased intracranial pressure, or right ventricular infarction.
MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia.
Take sublingual nitroglycerin at the first sign of chest pain; sit down before taking to prevent dizziness.,Place the tablet under the tongue or in the buccal pouch and allow it to dissolve completely; do not swallow.,If pain is not relieved within 5 minutes, call 911 immediately; you may take a second tablet while waiting.,Do not take this medication if you have taken erectile dysfunction drugs (e.g., sildenafil, tadalafil) within the last 24-48 hours.,Store sublingual tablets in the original glass bottle with the cap tightly closed to protect from light and moisture; do not transfer to another container.,Expect a headache or flushing after taking; these usually diminish with continued use.,If using a transdermal patch, apply to a hairless area of skin and rotate sites daily; remove at bedtime to prevent tolerance.,Avoid alcohol while taking this medication as it can increase the risk of hypotension.,Seek emergency help if you experience severe dizziness, fainting, or difficulty breathing.
Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily.,Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning.,Do not use for acute angina; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension.,Headache may occur; use acetaminophen or reduce dose; do not stop abruptly.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN vs MINITRAN, answered by our medical review team.
NITROGLYCERIN is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.. MINITRAN is a Nitrate Vasodilator that works by Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing c GMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN and MINITRAN depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN is: Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.. The standard adult dose of MINITRAN is: Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN and MINITRAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN is classified as Category C. Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution . MINITRAN is classified as Category C. Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.